Table 2 The baseline characteristics of 316 AML patients
Characteristics | Totality, n (%) | Median (range) |
|---|---|---|
Gender | 361 | Â |
 Male | 196 (54.3%) |  |
 Female | 165 (45.7%) |  |
Age | 361 | 43 (16–76) years |
FAB classification | ||
 M1 | 19 (5.3%) |  |
 M2 | 193 (53.5%) |  |
 M4 | 63 (17.5%) |  |
 M5 | 75 (20.8%) |  |
 M6 | 6 (1.7%) |  |
 Undefined | 5 (1.4%) |  |
WBC | 356 (98.6%) | 14.7 (0.4–426.0), × 109/L |
LDH | 341 (94.5%) | 363 (17–5853), U/L |
BM blast % | 348 (96.4%) | 71% (17–99%) |
RBC | 356 (98.6%) | 2.19 (0.67–4.98), × 1012/L |
Hemoglobin | 356 (98.6%) | 72 (27–149), g/L |
Platelets | 356 (98.6%) | 34 (2–546), × 109/L |
Neutrophil | 356 (98.6%) | 2.2 (0.0–340.3), × 109/L |
Risk stratifications | ||
 Low risk | 71 (19.7%) |  |
 Intermediate risk | 187 (51.8%) |  |
 High risk | 78 (21.6%) |  |
 Undefined | 25 (6.9%) |  |
FLT3-ITD mutation | ||
 Positive | 42 (11.6%) |  |
 Negative | 294 (81.4%) |  |
 Unknown | 25 (6.9%) |  |
NPM1 mutation | ||
 Positive | 67 (18.6%) |  |
 Negative | 269 (74.5%) |  |
 Unknown | 25 (6.9%) |  |
CEBPA mutation | ||
 Positive | 50 (13.9%) |  |
 Negative | 286 (79.2%) |  |
 Unknown | 25 (6.9%) |  |
Karyotype | ||
 Normal | 255 (70.6%) |  |
 Abnormal | 84 (23.3%) |  |
 Unknown | 22 (6.1%) |  |
Allo-HCT | ||
 Yes | 64 (17.7%) |  |
 No | 297 (82.3%) |  |
CR after two courses of induction therapy | ||
 Yes | 205 (56.8%) |  |
 No | 120 (33.2%) |  |
 Not evaluated | 36 (10.0%) |  |
Chemotherapy regimens | ||
 MA | 125 (34.6%) |  |
 IA | 86 (23.8%) |  |
 TA | 47 (13.0%) |  |
 DA | 31 (8.6%) |  |
 CAG | 52 (14.4%) |  |
 Other regimens | 20 (5.5%) |  |